Gilead's 4th-qtr sales and earnings beat expectations, as Harvoni soars

3 February 2016

US biotech giant Gilead Sciences (Nasdaq: GILD) saw its shares rise 2.2% to $84.48 in after-hours trading yesterday, following reporting of its fourth-quarter and full-year 2015 financial results, that beat analysts’ expectations.

For the final quarter earnings reached $4.89 billion, or $3.32 per share up 34% from $3.5 billion in the year-earlier quarter. Analysts had expected the company to earn $3.00 per share, according figures compiled by Thomson Reuters. Meanwhile, revenue for the quarter rose 16.4% to $8.5 billion, beating expectations of $8.2 billion.

Combined sales of the hepatitis C drugs recently-launched Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir) of $4.9 billion, exceeding analysts’ estimates of $4.5 billion. Sales of Harvoni totalled $3.35 billion, compared to expectations of $3.1 billion, while revenue from Sovaldi declined nearly 11% to $1.6 billion, ahead of expectations, as Harvoni took market share

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK